The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma

Sponsor
Carol Davila University of Medicine and Pharmacy (Other)
Overall Status
Recruiting
CT.gov ID
NCT04765410
Collaborator
Bucharest Emergency Hospital (Other), Institutul Clinic Fundeni (Other)
60
5
26.4
12
0.5

Study Details

Study Description

Brief Summary

Pancreatic adenocarcinoma still represents one of the "hot-topics" worldwide. Endoscopic ultrasonography was a breakthrough, bringing us closer to personalized treatment by getting histopathological samples through fine-needle-aspiration or fine-needle-biopsy. These samples can be analyzed and offer the possibility to detect a micro-RNA profile.

Micro-RNAs are small non-coding RNA molecules that interfere in genic expression. Many studies focused on seric microRNA profile, though there are many implications in tissue micro-RNA profile, thus overexpression or under expression of these molecules might help us not only understand different cellular processes, but also interfere in personalized medicine in the future.

The investigators propose a prospective, multicenter, randomized, cohort study on 60 patients with solid pancreatic masses to evaluate tissue microRNA profile obtained by EUS-FNA.

The primary hypothesis is to correlate the microRNA tissular expression in pancreatic adenocarcinoma with tumor aggressive behavior, survival and response to treatment.

The samples will be obtained from the participants during endoscopic ultrasonography, through fine needle aspiration, after consent was given to be a part of the study prior to the intervention. The probe will be preserved in a special recipient that stabilizes RNA and inhibits RNA-lazes, thus preventing RNA degradation by endogenous ribonucleases.

The analysis of miRNA profile will be made using qRT-PCR array method, by miScript II RT Kit, miScript SYBR Green PCR Kit și miScript miRNA PCR Array Human Cancer Pathway Finder (MIHS-102Z) (Qiagen, GmbH). Thus a kit containing a number of 84 miRNAs will be analysed in every participant.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: EUS FNA (endoscopic ultrasound fine needle aspiration)

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Tissue Micro-RNA Profile Collected Through Endoscopic Ultrasonography Fine-Needle-Aspiration (EUS-FNA) In Pancreatic Adenocarcinoma And Its Impact On Survival And Prognosis
Actual Study Start Date :
Mar 21, 2019
Anticipated Primary Completion Date :
Jun 1, 2021
Anticipated Study Completion Date :
Jun 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Patients with solid pancreatic masses

Patients with solid pancreatic masses

Diagnostic Test: EUS FNA (endoscopic ultrasound fine needle aspiration)
Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).

Outcome Measures

Primary Outcome Measures

  1. Mean change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status, weight and survival in patients with pancreatic adenocarcinoma according to tissue microRNA expression [through study completion, an average of 2 and a half years]

    Eastern Cooperative Oncology Group (ECOG) performance status, weight and survival will be assessed though different consultations (in person or by telemedicine): at first presentation, at 1 month, at 3 months, at 6 months and at one year.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Pancreatic solid mass, with or without a cystic component

  • Age over 18 years old

  • Signed informed consent

Exclusion Criteria:
  • Cystic pancreatic mass with no solid component

  • Abnormal coagulation (elevated INR >1.5, thrombocytopenia<60 000/mm3, activated partial thromboplastin time>42 seconds), participant on anticoagulant treatment that cannot stop the treatment

  • European Cooperative Oncology Group status 4

  • Pregnancy

  • Age under 18 years old

  • The participant does not want to sign the consent form, or is unable to

  • Difficult puncture position during endoscopic ultrasonography: vessels or Wirsung duct positioned in front of the needle (decision of the endoscopist)

Contacts and Locations

Locations

Site City State Country Postal Code
1 "Carol Davila" University Central Emergency Hospital Bucharest Sector 1 Romania 010825
2 "Prof Dr Agrippa Ionescu" Emergency Hospital Bucharest Sector 1 Romania 011356
3 Clinical Emergency Hospital Bucharest Bucharest Sector 1 Romania 014461
4 Fundeni Clinical Institute Bucharest Sector 2 Romania 022328
5 "Victor Babes" National Pathology Institute Bucharest Sector Romania 050096

Sponsors and Collaborators

  • Carol Davila University of Medicine and Pharmacy
  • Bucharest Emergency Hospital
  • Institutul Clinic Fundeni

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mihai Ciocirlan, MD PhD, Carol Davila University of Medicine and Pharmacy
ClinicalTrials.gov Identifier:
NCT04765410
Other Study ID Numbers:
  • PDACmiRNA
First Posted:
Feb 21, 2021
Last Update Posted:
Feb 21, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mihai Ciocirlan, MD PhD, Carol Davila University of Medicine and Pharmacy
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 21, 2021